KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Income from Continuing Operations: 2009-2025

Historic Income from Continuing Operations for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to -$30.7 million.

  • Biomarin Pharmaceutical's Income from Continuing Operations fell 128.98% to -$30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $520.4 million, marking a year-over-year increase of 61.47%. This contributed to the annual value of $426.9 million for FY2024, which is 154.62% up from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Income from Continuing Operations stood at -$30.7 million, which was down 112.78% from $240.5 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Income from Continuing Operations registered a high of $240.5 million during Q2 2025, and its lowest value of -$57.9 million during Q4 2021.
  • Its 3-year average for Income from Continuing Operations is $90.0 million, with a median of $88.7 million in 2024.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Income from Continuing Operations plummeted by 440.02% in 2021 and then soared by 8,282.73% in 2023.
  • Biomarin Pharmaceutical's Income from Continuing Operations (Quarterly) stood at -$57.9 million in 2021, then surged by 99.57% to -$249,000 in 2022, then soared by 8,282.73% to $20.4 million in 2023, then soared by 513.22% to $124.9 million in 2024, then tumbled by 128.98% to -$30.7 million in 2025.
  • Its Income from Continuing Operations stands at -$30.7 million for Q3 2025, versus $240.5 million for Q2 2025 and $185.7 million for Q1 2025.